PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods

(2016) Xiaohua Shi et al.   Scientific Reports

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

(2015) A. Wang et al.   EJSO

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

(2015) Wendy A. Cooper et al.   LUNG CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

(2015) Meghan Shea et al.   Therapeutic Advances in Respiratory Disease

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer

(2013) Julie R. Brahmer   JOURNAL OF CLINICAL ONCOLOGY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY